WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)

Saved in:

Bibliographic Details
Main Authors:	Jonathan Barratt, Sung Gyun Kim, Lesley A. Inker, David K. Packham, Dwarakanathan Ranganathan, Michelle N. Rheault, Mark Vishnepolsky, Yasmin Brahmbhatt, Yi Wang, Valeria Beckett, Seung Hyeok Han
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924023830
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Novel Treatment Paradigms: Primary IgA Nephropathy
by: Haresh Selvaskandan, et al.
Published: (2024-02-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial
by: Lihua Wang, et al.
Published: (2025-04-01)

IgG subclasses in symptomatic IgA deficiency
by: I Tezcan, et al.
Published: (1992-01-01)

Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study
by: Małgorzata Mizerska-Wasiak, et al.
Published: (2021-08-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Significance of serum IgA/C3 ratio in the diagnosis and prognosis of IgA nephropathy
by: XIE Wei-ji, et al.
Published: (2019-01-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns
by: Luisa Knecht, et al.
Published: (2024-12-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)

Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
by: Colin Reily, et al.
Published: (2014-01-01)

Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy
by: Hitoshi Irabu, et al.
Published: (2020-01-01)

Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
by: M. Colleen Hastings, et al.
Published: (2012-01-01)

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls
by: John T. Sanders, et al.
Published: (2017-01-01)

Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review
by: Areefa Alladin-Karan, et al.
Published: (2025-03-01)

IgA Nephropathy Associated with IgA Vasculitis Coexisting with Focal Segmental Glomerulosclerosis Tip Variant
by: Zitlali Guadalupe Paulín Zepeda, et al.
Published: (2023-07-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

Evaluation the Efficacy of ELISA IgG, IgM and IgA Tests for Diagnosis of Helicobacter pylori
by: Hogir Mohammed Shukri Saadi, et al.
Published: (2018-09-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

About selective IgA deficiency
by: Sinasi Ozsoylu
Published: (2011-12-01)

Application of hydroxychloroquine for IgA nephropathy
by: Xiao Yong-zhen, et al.
Published: (2021-01-01)

Unconventional T Cells in IgA Nephropathy
by: Zizhang Sheng, et al.
Published: (2025-02-01)